DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for inner ear disease — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInner ear disease maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inner ear disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2003 in vitro study tested four drugs — L-NAME (a nitric oxide synthase inhibitor), D-methionine (a radical scavenger), BDNF (a neurotrophin), and leupeptin (a calpain inhibitor) — for protection of vestibular hair cells against gentamicin toxicity. L-NAME blocked nitric oxide production; D-methionine and BDNF reduced reactive oxygen species; leupeptin affected neither. All four drugs individually limited hair cell damage. Combinations of L-NAME plus BDNF, L-NAME plus leupeptin, and D-methionine plus BDNF gave a significantly stronger preventive effect. The authors suggested combined treatment with a radical inhibitor and either a neurotrophin or calpain inhibitor might treat inner ear disorders more effectively, but this remains an in vitro finding with no human data.
Multiple reviews from 2001 through 2025 describe the shift from systemic to local drug delivery for inner ear disease — intratympanic injection, round window microcatheters, hydrogels, nanoparticles, and osmotic pumps. Animal data indicate sustained delivery systems produce more reliable inner ear pharmacokinetics than systemic or intratympanic routes. Gene therapy, first reported in the inner ear in 1996, has progressed in animal models to deliver protective genes for spiral ganglion neurons and hair cells, and to attempt hair cell regeneration through phenotype transformation. As of 2005, no specific drugs were targeted at inner ear disease, and gene therapy work was confined to animal models of ototoxicity and ischaemia-reperfusion injury.
The 2010 review noted that novel delivery techniques were still in various stages of clinical development. The 2005 gene therapy review stated that research was transitioning from marker genes to therapeutic genes in animal models. The 2001 perfusion review emphasised that clinical efforts had been hampered by a lack of basic science data on delivery system, agent choice, dosage, and duration. The 2009 historical perspective stressed that understanding mechanism-specific damage at specific cochlear sites is crucial for site-specific interventions.
What is still missing: no randomised controlled trials in humans for any of the proposed drug combinations or gene therapies; no established dosing, schedule, or duration for local perfusion; no validated patient stratification by injury mechanism or cochlear sub-site; and no approved drug specifically for inner ear disease. The field has promising animal data and delivery platforms, but lacks the clinical evidence and funding needed to move beyond proof-of-concept.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2010 · 51 citations
Round window perfusion dynamics: implications for intracochlear therapy
AbstractPURPOSE OF REVIEW: The treatments for inner ear diseases are evolving as the systemic administration of medication is replaced by novel intratympanic and intracochlear drug delivery. The current review explores the background and recent developments in this field. RECENT FINDINGS: Although still in various stages of clinical development, novel drug delivery techniques such as the Silverstein MicroWick, the round window microcatheter, biodegradable hydrogels, biopolymers, nanoparticles, newly designed cochlear implant arrays, osmotic mini/micro pumps, and reciprocating perfusion systems hold significant promise. Animal data suggest that sustained delivery systems have more reliable inner ear pharmacokinetics than both systemic administration and intratympanic injections. SUMMARY: As research scientists advance technologies for treating inner ear diseases, drug delivery techniques must keep pace. Viable treatment options for sensorineural hearing loss, tinnitus, and vestibular disorders are on the horizon and may usher in a new golden age for otology.
Neuroprotection of Vestibular Sensory Cells from Gentamicin Ototoxicity Obtained Using Nitric Oxide Synthase Inhibitors, Reactive Oxygen Species Scavengers, Brain-derived Neurotrophic Factors and Calpain Inhibitors
AbstractOBJECTIVE: In order to devise a new treatment for inner ear disorders, the efficacy of a nitric oxide synthase inhibitor (L-N(G)-nitroarginine methylester [L-NAME]), a radical scavenger (D-methionine), a neurotrophin (brain-derived neurotrophic factor [BDNF]) and a calpain inhibitor (leupeptin) for protection from hair cell damage was investigated. MATERIAL AND METHODS: The effects of these drugs on gentamicin-induced production of nitric oxide (NO) and reactive oxygen species (ROS) were studied by means of the fluorescence indicators 4,5-diaminofluorescein diacetate and dihydrotetramethylrosamine. The effect on gentamicin-induced vestibular hair cell damage was examined by using an in vitro LIVE/DEAD system. RESULTS: L-NAME inhibited the production of NO, D-methionine and BDNF restricted the production of ROS and leupeptin inhibited neither NO nor ROS. All the drugs used limited the vestibular hair cell damage caused by gentamicin. The combinations L-NAME + BDNF, L-NAME + leupeptin and D-methionine + BDNF had a significantly stronger preventive effect on hair cell damage. CONCLUSION: It is suggested that combined treatment with a radical inhibitor and either a neurotrophin or calpain inhibitor may help to treat inner ear disorders more effectively.
Advanced Science · 2025 · 13 citations · open access
Rational Design of Inner Ear Drug Delivery Systems
AbstractThe number of people with hearing loss disorders is enormous, causing great physical and mental stress to patients, as well as a huge social burden. Among these patients, hearing loss caused by inner ear lesions accounts for a large proportion. Therefore, treatment of the inner ear is important. Inner ear drug delivery systems, which can reduce the side effects of systemic drug administration by delivering drugs directly to the inner ear, are important in sensorineural hearing loss. Here, the development of inner ear drug delivery systems is focused, including the complex physiological structure that they face, types of drugs delivered, routes of administration, and forms of drug delivery carrier platforms. Recent studies in this process are presented and it is concluded with a summary and outlook on the problems faced and possible solutions.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2005 · 12 citations
Advances in inner ear gene therapy: exploring cochlear protection and regeneration
AbstractPURPOSE OF REVIEW: To review the application of gene therapy in the inner ear. Gene delivery to the inner ear was first reported in 1996. Since then the field has progressed on multiple fronts. RECENT DEVELOPMENTS: More diverse and sophisticated vectors are improving the efficiency of delivery to the inner ear. Research is transitioning from the delivery of marker genes to the delivery of therapeutic genes in animal models of inner ear disease. Three distinct areas of research are developing: (1) delivery of genes for protection of spiral ganglion neurons with potential application in cochlear implantation, (2) delivery of genes for protection of hair cells and hearing preservation in degenerative diseases and cochlear insults and (3) the use of gene therapy to transform cells from one phenotype to another and replace lost cells, potentially restoring lost function. SUMMARY: Currently, no specific drugs are targeted at inner ear disease. The use of gene therapy in the inner ear is being applied in animal models of ototoxicity and ischemia reperfusion injury. Gene therapy can protect the inner ear from damage and even restore function through the regeneration of hair cells.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2009 · 10 citations
Inner ear protection and regeneration: a ‘historical’ perspective
AbstractPURPOSE OF REVIEW: In evaluating strategies to preserve or regenerate the cochlea, understanding the process of labyrinthine injury on a cellular and molecular level is crucial. Examination of inner ear injury reveals mechanism-specific types of damage, often at specific areas within the cochlea. Site-specific interventions can then be considered. RECENT FINDINGS: The review will briefly summarize the historical perspective of advancements in hearing science through 2006. Areas of research covered include hair cell protection, hair cell regeneration, spiral ganglion cell regeneration, and stria vascularis metabolic regulation. SUMMARY: The review will briefly summarize the early development of a few such site-specific interventions for inner ear functional rehabilitation, for work done prior to 2006. The outstanding reviews of cutting edge research from this year's and last year's Hearing Science section of Current Opinion in Otolaryngology - Head and Neck Surgery can then be understood and appreciated in a more informed manner.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2001 · 2 citations
Perfusion of the inner ear: basic science considerations
AbstractFor many years, formidable physiologic and anatomic barriers to management of the inner ear have existed, limiting our ability to manage symptoms such as vertigo, tinnitus, and sensorineural hearing loss. Local application of drugs to the inner ear has recently gained favor as a method of managing inner ear disease while avoiding systemic side effects. Clinical efforts, however, have been hampered by a lack of basic science data. Until the past few years, few studies existed upon which to base decisions on delivery system, choice of agent, dosage range and schedule, and duration of therapy. Concepts presented recently provide not only some scientific framework for clinical treatment but also intriguing possibilities for new and innovative therapy. Although much work remains to be done, a basic science foundation for the use of inner ear perfusion is beginning to appear.
Therapeutic Delivery · 2025 · 1 citations · open access
Intratympanic injection of emulsion-like dispersions to co-deliver cinnarizine and morin hydrate-lipoid E80 complex in a rabbit inner ear model
AbstractBACKGROUND: Drug delivery to perilymph after crossing the round window membrane is paramount important for inner ear disease management. Intratympanic (IT) injection of emulsion-like dispersions augments cinnarizine (CNZ) and morin hydrate (MH)-Lipoid E80 complex permeation into perilymph in a healthy rabbit inner ear model. METHODS: A Box-Behnken design (BBD) followed by artificial neural network (ANN)-linked Levenberg - Marquardt (LM) algorithm was used for optimizing the injection formula. Immediately after 30-120 minutes post-IT injections, the concentration levels of CNZ and MH in both perilymph and plasma were monitored. RESULTS: The ANN-linked LM algorithm displayed lower prediction and mean squared errors as well as higher correlation coefficient values for all responses when compared to the corresponding values shown by BBD. The IT injections possessed 156.8 ± 8.5 nm mean particle size, 42.70 ± 4.20 mV zeta potential, >98% CNZ and MH release within 10-20 minutes dissolution in pH 7.4 artificial perilymph solution, >97.26% cell viability in MTT assay and near normal histopathology. The 63.07 ± 23.62 µg/ml CNZ and 82.51 ± 8.33 µg/ml MH were attained in perilymph at 60 minutes post-IT injections. CONCLUSION: The IT-injected formulation can be used to co-deliver two drugs in perilymph for managing inner ear diseases.
Korean Journal of Otorhinolaryngology - Head and Neck Surgery · 2014 · 1 citations
Intratympanic Drug Injection for Inner Ear Disease
AbstractDuring treatment of inner ear diseases, the blood-cochlear barrier limits the drug delivery into the cochlea. Intratympanic drug injection for inner ear diseases is a safe procedure where drugs reach high concentrations in the cochlea and systemic side effects are minimized. This paper reviews the updated status of intratympanic drug injections for the treatment of inner ear disease. Intratympanic drug injection is an effective procedure for the control of inner ear disorders such as Meniere’s disease and sudden sensorineural hearing loss. Although the effect of intratympanic injection on tinnitus and noise-induced hearing loss is open to discussion, its indications could be extended, like as drug, gene, and cell-based therapy. � Korean J Otorhinolaryngol-Head Neck Surg 2014;57(6):364-72 Key WordsZZAminoglycosides ㆍMeniere disease ㆍNoise induced hearing loss ㆍSteroid ㆍ Sudden hearing loss ㆍTinnitus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
